{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T04:05:41Z","timestamp":1751256341692,"version":"3.41.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"am","delay-in-days":362,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006556","name":"CHU Toulouse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006556","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.revmed.2024.11.011","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T17:56:21Z","timestamp":1732298181000},"page":"369-376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Revue des atteintes dermatologiques atypiques et\/ou syst\u00e9miques en lien avec les inhibiteurs de checkpoints immunologiques"],"prefix":"10.1016","volume":"46","author":[{"given":"Val\u00e9rian","family":"Rivet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Sibaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00e9mie","family":"Dion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salom\u00e9","family":"Duteurtre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lanie","family":"Biteau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Pages","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9a","family":"Pastissier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Delavigne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Cougoul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odile","family":"Rauzy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibault","family":"Comont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2024.11.011_bib0305","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nrc3153","article-title":"Novel cancer immunotherapy agents with survival benefit: recent successes and next steps","volume":"11","author":"Sharma","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.revmed.2024.11.011_bib0310","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab an Ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2024.11.011_bib0315","doi-asserted-by":"crossref","first-page":"iv254","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicites from imunotherapy: ESMO clinical practice guidlines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.revmed.2024.11.011_bib0320","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.revmed.2019.09.005","article-title":"Toxicit\u00e9s immunologiques induites par les inhibiteurs de checkpoint en 2019\u00a0: mise au point","volume":"41","author":"Comont","year":"2020","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2024.11.011_bib0325","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockage","volume":"378","author":"Postow","year":"2018","journal-title":"N Eng J Med"},{"key":"10.1016\/j.revmed.2024.11.011_bib0330","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.revmed.2024.11.011_bib0335","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1203475420943260","article-title":"Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management","volume":"25","author":"Muntyanu","year":"2021","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.revmed.2024.11.011_bib0340","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2147\/CCID.S364243","article-title":"Skin manifestation induced by immune checkpoint inhibitors","volume":"10","author":"Yamamoto","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.revmed.2024.11.011_bib0345","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/1346-8138.14160","article-title":"Diagnostic criteria, severity classification and guidelines of eosinophilic fasciitis","volume":"45","author":"Jinnin","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.revmed.2024.11.011_bib0350","first-page":"S0248","article-title":"[Eosinophilic fasciitis: from pathophysiology to therapeutics]","volume":"24","author":"Knapp","year":"2024","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2024.11.011_bib0355","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamadermatol.2015.3648","article-title":"Epidemiology and treatment of eosinophilic fasciitis: an analysis of 63\u00a0patients from 3\u00a0tertiary care centers","volume":"152","author":"Wright","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.revmed.2024.11.011_bib0360","first-page":"493","article-title":"Eosinophilic fasciitis. A pathologic study of twenty cases","volume":"96","author":"Barnes","year":"1979","journal-title":"Am J Pathol"},{"key":"10.1016\/j.revmed.2024.11.011_bib0365","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.revmed.2015.08.002","article-title":"[Eosinophilic fasciitis (Shulman's disease): diagnostic and therapeutic review]","volume":"36","author":"S\u00e8ne","year":"2015","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2024.11.011_bib0370","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jaad.2022.08.026","article-title":"Cluster analysis reveals eosinophilia and fibrosis as poor prognostic markers in 128\u00a0patients with eosinophilic fasciitis","volume":"87","author":"Chaigne","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.revmed.2024.11.011_bib0375","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4\u00a0and PD-1\/PD-L1\u00a0inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.revmed.2024.11.011_bib0380","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.jaad.2021.05.030","article-title":"Drug-induced eosinophilic fasciitis: a dual pharmacovigilance analysis","volume":"86","author":"Teboul","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"S1","key":"10.1016\/j.revmed.2024.11.011_bib0385","doi-asserted-by":"crossref","first-page":"A94","DOI":"10.1016\/j.revmed.2024.04.390","article-title":"Fasciite \u00e0 \u00e9osinophiles induite par les Inhibiteurs du checkpoint immunologique\u00a0: s\u00e9rie de cas et revue de la litt\u00e9rature","volume":"45","author":"Biteau","year":"2024","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2024.11.011_bib0390","doi-asserted-by":"crossref","first-page":"114065","DOI":"10.1016\/j.ejca.2024.114065","article-title":"Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockers","volume":"204","author":"Cariou","year":"2024","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.revmed.2024.11.011_bib0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.revmed.2023.12.003","article-title":"Gestion des toxicit\u00e9s des immunoth\u00e9rapies du cancer\u00a0: challenges et \u00ab\u00a0rechallenges\u00a0\u00bb pour les (jeunes) internistes","volume":"45","author":"Guitton","year":"2024","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2024.11.011_bib0400","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheuma Dis"},{"issue":"8","key":"10.1016\/j.revmed.2024.11.011_bib0405","doi-asserted-by":"crossref","first-page":"102586","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities","volume":"19","author":"Allenbach","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.revmed.2024.11.011_bib0410","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1136\/annrheumdis-2020-217018","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO's adverse drug reactions database","volume":"81","author":"Nguyen","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.revmed.2024.11.011_bib0415","doi-asserted-by":"crossref","first-page":"103375","DOI":"10.1016\/j.autrev.2023.103375","article-title":"Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature","volume":"22","author":"Guerra","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"S1","key":"10.1016\/j.revmed.2024.11.011_bib0420","doi-asserted-by":"crossref","first-page":"A127","DOI":"10.1016\/j.revmed.2024.04.433","article-title":"Dermatomyosites induites par les inhibiteurs du checkpoint immunologique\u00a0: s\u00e9rie de cas, recueil issu de la base de pharmacovigilance VigiBase et revue de la litt\u00e9rature","volume":"45","author":"Duteurtre","year":"2024","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2024.11.011_bib0425","first-page":"462","article-title":"Pouss\u00e9e s\u00e9v\u00e8re d\u2019une dermatomyosite pr\u00e9-existante chez une patiente avec un ad\u00e9nocarcinome pulmonaire trait\u00e9 par pembrolizumab, un anti-PD-1","volume":"77","author":"Chauveheid","year":"2022","journal-title":"Rev Med Liege"},{"issue":"1","key":"10.1016\/j.revmed.2024.11.011_bib0430","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s40425-019-0821-8","article-title":"Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1\u00a0or anti-PD-L1\u00a0immunotherapies, a descriptive study","volume":"7","author":"Manson","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.revmed.2024.11.011_bib0435","doi-asserted-by":"crossref","first-page":"e008724","DOI":"10.1136\/jitc-2023-008724","article-title":"Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes","volume":"12","author":"Nassar","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.revmed.2024.11.011_bib0440","doi-asserted-by":"crossref","first-page":"102596","DOI":"10.1016\/j.autrev.2020.102596","article-title":"Risk of scleroderma according to the type of immune checkpoint inhibitors","volume":"9","author":"Terrier","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2024.11.011_bib0445","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1159\/000533373","article-title":"Scleroderma secondary to pembrolizumab: a case report and review of 19\u00a0cases of anti-pd-1-induced scleroderma","volume":"6","author":"Farrugia","year":"2023","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.revmed.2024.11.011_bib0450","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40801-023-00399-7","article-title":"Immune checkpoint inhibitors and scleroderma: data from the european pharmacovigilance database","volume":"11","author":"Nicoletti","year":"2024","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.revmed.2024.11.011_bib0455","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1002\/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-K","article-title":"Increased interleukin-17\u00a0production in patients with systemic sclerosis","volume":"43","author":"Kurasawa","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2024.11.011_bib0460","first-page":"78","article-title":"Paraneoplastic scleroderma: are there any clues?","volume":"24","author":"Jedlickova","year":"2016","journal-title":"Acta Dermatovenerol Croat"},{"year":"2022","series-title":"Protocole national de diagnostic et de soins (PNDS) sur la scl\u00e9rodermie syst\u00e9mique, Fai2r","author":"Hachulla","key":"10.1016\/j.revmed.2024.11.011_bib0465"},{"key":"10.1016\/j.revmed.2024.11.011_bib0470","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/BOR.0000000000000222","article-title":"Cancer and scleroderma: a paraneoplasic disease with implications for malignancy screening","volume":"27","author":"Shah","year":"2015","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.revmed.2024.11.011_bib0475","doi-asserted-by":"crossref","first-page":"e14618","DOI":"10.1111\/dth.14618","article-title":"Challenges in sarcoidosis and sarcoid-like reactions associated to immune checkpoint inhibitors: a narrative review apropos of a case","volume":"34","author":"Apalla","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.revmed.2024.11.011_bib0480","doi-asserted-by":"crossref","first-page":"594118","DOI":"10.3389\/fmed.2020.594118","article-title":"Sarcoidosis and cancer: a complex relationship","volume":"7","author":"El Jammal","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.revmed.2024.11.011_bib0485","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jdcr.2016.05.002","article-title":"Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy","volume":"2","author":"Suozzi","year":"2016","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.revmed.2024.11.011_bib0490","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-216217","article-title":"Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition","author":"Kim","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.revmed.2024.11.011_bib0495","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/dth.12380","article-title":"Cutaneous sarcoidosis in a melanoma patient under Ipilimumab therapy","volume":"29","author":"Martinez Leborans","year":"2016","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.revmed.2024.11.011_bib0500","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/j.jaad.2013.07.028","article-title":"Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab","volume":"69","author":"Reule","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.revmed.2024.11.011_bib0505","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jdcr.2016.06.004","article-title":"Pembrolizumab-associated sarcoidosis","volume":"2","author":"Cotliar","year":"2016","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.revmed.2024.11.011_bib0510","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1200\/JCO.2011.39.3298","article-title":"Pulmonary sarcoid-like granulomatosis induced by ipilimumab","volume":"30","author":"Berthod","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2024.11.011_bib0515","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.chest.2015.10.082","article-title":"Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma","volume":"149","author":"Danlos","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.revmed.2024.11.011_bib0520","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jdcr.2017.02.015","article-title":"Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma","volume":"3","author":"Birnbaum","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.revmed.2024.11.011_bib0525","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jtho.2018.04.031","article-title":"Sarcoidosis-like reactions induced by checkpoint inhibitors","volume":"13","author":"Gkiozos","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.revmed.2024.11.011_bib0530","doi-asserted-by":"crossref","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur J Respir"},{"key":"10.1016\/j.revmed.2024.11.011_bib0535","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/CJI.0000000000000457","article-title":"Pembrolizumab-induced acral vasculitis","volume":"46","author":"Yohannan","year":"2023","journal-title":"J Immunother"},{"key":"10.1016\/j.revmed.2024.11.011_bib0540","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors-a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.revmed.2024.11.011_bib0545","doi-asserted-by":"crossref","first-page":"152440","DOI":"10.1016\/j.semarthrit.2024.152440","article-title":"A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: unraveling the complexities at the intersection of immunology and vascular pathology","volume":"66","author":"Lee","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2024.11.011_bib0550","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s13691-020-00454-y","article-title":"Limb arteriolar vasculitis induced by pembrolizumab plus chemotherapy in a patient with lung cancer","volume":"10","author":"Takada","year":"2020","journal-title":"Int Cancer Conf"},{"key":"10.1016\/j.revmed.2024.11.011_bib0555","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2340\/00015555-2504","article-title":"Acute lower limb ischaemia and diabetes in a patient treated with anti-PD1\u00a0monoclonal antibody for metastatic melanoma","volume":"97","author":"Thoreau","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.revmed.2024.11.011_bib0560","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40425-018-0321-2","article-title":"Ipilimumab induced digital vasculitis","volume":"6","author":"Padda","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.revmed.2024.11.011_bib0565","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12885-019-5661-x","article-title":"Acral vascular necrosis associated with immune-check point inhibitors: case report with literature review","volume":"19","author":"Khaddour","year":"2019","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.revmed.2024.11.011_bib0570","doi-asserted-by":"crossref","first-page":"e233463","DOI":"10.1136\/bcr-2019-233463","article-title":"Acral vascular syndrome during an immune checkpoint inhibitor","volume":"13","author":"O\u2019Connor","year":"2020","journal-title":"BMJ Case Rep"},{"year":"2017","series-title":"Version 5.0","key":"10.1016\/j.revmed.2024.11.011_bib0575"},{"issue":"1","key":"10.1016\/j.revmed.2024.11.011_bib0580","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12885-017-3313-6","article-title":"Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade","volume":"17","author":"Gambichler","year":"2017","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.revmed.2024.11.011_bib0585","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s40425-018-0443-6","article-title":"Immune checkpoint inhibitor-related acral vasculitis","volume":"6","author":"Comont","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.revmed.2024.11.011_bib0590","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2217\/imt-2018-0082","article-title":"Nivolumab-associated digital small-vessel vasculitis in a patient with an advanced renal cell carcinoma","volume":"11","author":"Franco","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.revmed.2024.11.011_bib0595","first-page":"e970","article-title":"Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis","volume":"114","author":"Zhang","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.revmed.2024.11.011_bib0300","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1097\/MD.0000000000000047","article-title":"Digital ischemia associated with cancer: results from a cohort study","volume":"93","author":"Le Besnerais","year":"2014","journal-title":"Medecine (Baltimore)"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866324012943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866324012943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T16:35:51Z","timestamp":1751214951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866324012943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0248866324012943"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2024.11.011","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revue des atteintes dermatologiques atypiques et\/ou syst\u00e9miques en lien avec les inhibiteurs de checkpoints immunologiques","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2024.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}